146 related articles for article (PubMed ID: 17343372)
1. Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor.
Dai Y; Hartandi K; Ji Z; Ahmed AA; Albert DH; Bauch JL; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Harris CM; Hickman D; Guo J; Li J; Marcotte PA; Marsh KC; Moskey MD; Martin RL; Olson AM; Osterling DJ; Pease LJ; Soni NB; Stewart KD; Stoll VS; Tapang P; Reuter DR; Davidsen SK; Michaelides MR
J Med Chem; 2007 Apr; 50(7):1584-97. PubMed ID: 17343372
[TBL] [Abstract][Full Text] [Related]
2. Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition.
Franklin PH; Banfor PN; Tapang P; Segreti JA; Widomski DL; Larson KJ; Noonan WT; Gintant GA; Davidsen SK; Albert DH; Fryer RM; Cox BF
J Pharmacol Exp Ther; 2009 Jun; 329(3):928-37. PubMed ID: 19255283
[TBL] [Abstract][Full Text] [Related]
3. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.
Dai Y; Guo Y; Frey RR; Ji Z; Curtin ML; Ahmed AA; Albert DH; Arnold L; Arries SS; Barlozzari T; Bauch JL; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Marsh KC; Moskey MD; Pease LJ; Stewart KD; Stoll VS; Tapang P; Wishart N; Davidsen SK; Michaelides MR
J Med Chem; 2005 Sep; 48(19):6066-83. PubMed ID: 16162008
[TBL] [Abstract][Full Text] [Related]
4. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.
Albert DH; Tapang P; Magoc TJ; Pease LJ; Reuter DR; Wei RQ; Li J; Guo J; Bousquet PF; Ghoreishi-Haack NS; Wang B; Bukofzer GT; Wang YC; Stavropoulos JA; Hartandi K; Niquette AL; Soni N; Johnson EF; McCall JO; Bouska JJ; Luo Y; Donawho CK; Dai Y; Marcotte PA; Glaser KB; Michaelides MR; Davidsen SK
Mol Cancer Ther; 2006 Apr; 5(4):995-1006. PubMed ID: 16648571
[TBL] [Abstract][Full Text] [Related]
5. ABT-869, a multitargeted receptor tyrosine kinase inhibitor, reduces tumor microvascularity and improves vascular wall integrity in preclinical tumor models.
Jiang F; Albert DH; Luo Y; Tapang P; Zhang K; Davidsen SK; Fox GB; Lesniewski R; McKeegan EM
J Pharmacol Exp Ther; 2011 Jul; 338(1):134-42. PubMed ID: 21505059
[TBL] [Abstract][Full Text] [Related]
6. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
[TBL] [Abstract][Full Text] [Related]
7. 3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases.
Ji Z; Ahmed AA; Albert DH; Bouska JJ; Bousquet PF; Cunha GA; Diaz G; Glaser KB; Guo J; Harris CM; Li J; Marcotte PA; Moskey MD; Oie T; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR
J Med Chem; 2008 Mar; 51(5):1231-41. PubMed ID: 18260617
[TBL] [Abstract][Full Text] [Related]
8. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
Glaser KB; Li J; Marcotte PA; Magoc TJ; Guo J; Reuter DR; Tapang P; Wei RQ; Pease LJ; Bui MH; Chen Z; Frey RR; Johnson EF; Osterling DJ; Olson AM; Bouska JJ; Luo Y; Curtin ML; Donawho CK; Michaelides MR; Tse C; Davidsen SK; Albert DH
J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
[TBL] [Abstract][Full Text] [Related]
9. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas.
Kubo K; Shimizu T; Ohyama S; Murooka H; Iwai A; Nakamura K; Hasegawa K; Kobayashi Y; Takahashi N; Takahashi K; Kato S; Izawa T; Isoe T
J Med Chem; 2005 Mar; 48(5):1359-66. PubMed ID: 15743179
[TBL] [Abstract][Full Text] [Related]
10. A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.
Zhang J; Zhou J; Ren X; Diao Y; Li H; Jiang H; Ding K; Pei D
Invest New Drugs; 2012 Apr; 30(2):490-507. PubMed ID: 21080210
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.
Sun Y; Shan Y; Li C; Si R; Pan X; Wang B; Zhang J
Eur J Med Chem; 2017 Dec; 141():373-385. PubMed ID: 29032031
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.
Guagnano V; Furet P; Spanka C; Bordas V; Le Douget M; Stamm C; Brueggen J; Jensen MR; Schnell C; Schmid H; Wartmann M; Berghausen J; Drueckes P; Zimmerlin A; Bussiere D; Murray J; Graus Porta D
J Med Chem; 2011 Oct; 54(20):7066-83. PubMed ID: 21936542
[TBL] [Abstract][Full Text] [Related]
13. ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats.
Banfor PN; Franklin PA; Segreti JA; Widomski DL; Davidsen SK; Albert DH; Cox BF; Fryer RM; Gintant GA
J Cardiovasc Pharmacol; 2009 Feb; 53(2):173-8. PubMed ID: 19188829
[TBL] [Abstract][Full Text] [Related]
14. ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft.
Jasinghe VJ; Xie Z; Zhou J; Khng J; Poon LF; Senthilnathan P; Glaser KB; Albert DH; Davidsen SK; Chen CS
J Hepatol; 2008 Dec; 49(6):985-97. PubMed ID: 18930332
[TBL] [Abstract][Full Text] [Related]
15. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Patyna S; Laird AD; Mendel DB; O'farrell AM; Liang C; Guan H; Vojkovsky T; Vasile S; Wang X; Chen J; Grazzini M; Yang CY; Haznedar JO; Sukbuntherng J; Zhong WZ; Cherrington JM; Hu-Lowe D
Mol Cancer Ther; 2006 Jul; 5(7):1774-82. PubMed ID: 16891463
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Preliminary Cytotoxicity Studies of 1-[1-(4,5-Dihydrooxazol- 2-yl)-1H-indazol-3-yl]-3-phenylurea and 3-phenylthiourea Derivatives.
Kornicka A; Saczewski F; Bednarski PJ; Korcz M; Szumlas P; Romejko E; Sakowicz A; Sitek L; Wojciechowska M
Med Chem; 2017; 13(7):616-624. PubMed ID: 28266278
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.
Gangjee A; Namjoshi OA; Yu J; Ihnat MA; Thorpe JE; Warnke LA
Bioorg Med Chem; 2008 May; 16(10):5514-28. PubMed ID: 18467105
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors.
Guo J; Marcotte PA; McCall JO; Dai Y; Pease LJ; Michaelides MR; Davidsen SK; Glaser KB
Mol Cancer Ther; 2006 Apr; 5(4):1007-13. PubMed ID: 16648572
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
[TBL] [Abstract][Full Text] [Related]
20. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]